Partnership First
Every deal must work for the developer, the commercial partner, and the patient. That's how relationships last twenty years.
Global PharmaPartners, Inc. was founded in 2006 by Rob Camerer with a clear mission: bring high-value pharmaceutical developments from Europe and beyond to the USA and Canada — and license them to world-class pharmaceutical customers.
GPP acquires and licenses pharmaceutical dossiers from top U.S., EU, and global R&D companies. Through time, we have created significant business for our global R&D partners — with total global investment raised by GPP in excess of $500 million USD, and revenues in the coming years for all products signed measured in the billions of dollars.
Today, GPP has grown to be a household name in the USA and abroad, with product licensing experience in over 89 countries and a focus on the USA and Canada. We are experiencing growth and profitability year after year.
We are positioned to support both our development partners and our pharmaceutical customer base in the global markets — with excellent products for today and for the future.
Rob Camerer establishes Global PharmaPartners to bring high-value pharmaceutical developments from Europe to North America.
GPP builds its reputation in generic pharma licensing, expanding its R&D partner roster and its network of U.S. commercial customers.
The portfolio broadens dramatically: Specialty Pharma, 505(b)(2) hybrids, innovative drug developments, and drug/medical device combinations.
GPP continues to expand into biologics — applying the same proven licensing model to the next generation of medicine.
Every deal must work for the developer, the commercial partner, and the patient. That's how relationships last twenty years.
Licensing experience in 89 countries, concentrated where it matters most for our partners: the United States and Canada.
We select for quality and real commercial opportunity — products with a future, not just a filing.
GPP's results come from experienced people who know both sides of every deal.